ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc.antibody_drug_conjugatePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
1411 Active assets in the Locally Advanced or Metastatic Malignant Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nabiximols Jazz Pharmaceuticals | Phase 3 | BBB |
Vitamin B6 M.D. Anderson Cancer Center | Phase 4 | BB |
Inno-206 M.D. Anderson Cancer Center | Phase 2 | BB |
PROPOFOL Hong Kong Children's Hospital | Phase 4 | BB |
Desflurane Peter MacCallum Cancer Centre, Australia | Phase 4 | BB |
View all 50 →
Same molecule, other indications
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →